Review: Present and future directions in the treatment of chronic hepatitis B infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 12, 1997, Pages 843-854

  Nicoll, Amanda ^a   Locarnini, Stephen ^a  

^a FAIRFIELD HOSPITAL   (Australia)

Author keywords

Chemotherapeutic agents; Chronic hepatitis B; Combination antiviral therapy; Interferon alpha; Nucleoside analogues

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; FAMCICLOVIR; FIALURIDINE; FOSCARNET; GAMMA INTERFERON; GANCICLOVIR; IMMUNOMODULATING AGENT; INTERLEUKIN 2; LAMIVUDINE; LEVAMISOLE; NUCLEOSIDE ANALOG; PENCICLOVIR; PURINE NUCLEOSIDE DERIVATIVE; PYRIMIDINE NUCLEOSIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

AUSTRALIA; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; HEPATITIS B; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; VIRUS PATHOGENESIS;

EID: 0031407309     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00382.x     Document Type: Review

References (134)

1. Beasley RP, Hwang LY, Lin CC et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-33.
2. Davies SE, Portmann BC, O'Grady JG et al. Hepatic histological findings alter transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1941; 13: 150-57.
3. Hoofnagle JH, Peters M, Mullen KD et al. Randomised, controlled trial of recombinant human α-Interferon in patients with chronic hepatitis B. 1988; 95: 1318-25.
4. Feinman SV, Berris B, Sooknanan R et al. Effects of Interferon-α therapy on serum and liver HBV DNA in patients with chronic hepatitis B. Dig. Dis. Sci. 1992; 37: 1477-82.
5. Korenman J, Baker B, Waggoner J et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Intern. Med. 1991; 114: 629-34.
6. Shaw T, Locarnini S. Hepatic purine and pyrimidine metabolism: Implications for antiviral chemotherapy of viral hepatitis. Liver 1995; 15: 169-84.
7. Andreone P, Cursarro C, Gramenzi A et al. A randomized controlled trial of thymosin-α1 versus interferon alfa treatment in patients with hepatitis Be antigen antibody and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 1996; 24: 774-7.
8. Sztein MB, Goldstein AL. Thymic hormones: A clinical update. Springer Semin. Immunopathol. 1986; 9: 1-18.
9. Mutchnick MG, Appelman HD, Chung HT et al. Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial. Hepatology 1991; 14: 409-15.
10. Low T, Thurman G, McAdoo M et al. Isolation, characterisation and biological activities of thymosin α1 and polypeptide β1 from calf thymus. J. Biol. Chem. 1979; 254: 981-6.
11. Guidotti L, Guilhot S, Chisari F. Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumour necrosis factor-dependent and -independent pathways. J. Virol. 1994; 68: 1265-70.
12. Guilhot S, Guidotti L, Chisari F. Interleukin-2 down-regulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism. J. Virology 1993; 67: 7444-9.
13. Rossol S, Marinos G, Carucci P et al. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. Hepatology 1996; 24: 283A (Abstract).
14. Ho D. Time to hit HIV, early and hard. N. Eng. J. Med. 1995; 333: 450-51.
15. Richman D. HIV therapeutics. Science 1996; 272: 1886-8.
16. Locarnini S, Gust I. Hepadnaviridae: Hepatitis B virus and the delta virus. In: Lennette EH, Halonen P, Murphy FA, eds. Laboratory diagnosis of infectious diseases principles and practice, vol. 2. New York: Springer-Verlag, 1988; 750-96.
17. Hoofnagle J, Shafritz D, Popper H. Chronic type B hepatitis and the 'healthy' HBsAg carrier state. Hepatology 1987; 7: 758-63.
18. Tassopoulos N, Papaevangelou G, Sjogren M et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987; 92: 1844-50.
19. Bortolotti F. Chronic hepatitis B acquired in childhood: unanswered questions and evolving issues. J. Hepatol. 1994; 21: 904-9.
20. Lok ASF, Lai C-L. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J. Hepatol. 1990; 10: 29-34.
21. Milich DR, Jones JE, Hughes JL et al. Is a function of the secreted hepatitis Be antigen to induce immunological tolerance in utero? Proc. Natl Acad. Sci. USA 1990; 87: 6599-603.
22. Hadziyannis S. Hepatitis Be antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hep. Rev. 1995; 1: 7-36.
23. Locarnini SA. Design of new anti-viral agents for chronic hepatitis B virus infection. J. Gastroenterol. Hepatol. 1991; 1 (Suppl): 18-22.
24. Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu. Rev. Biochem. 1987; 56: 651-93.
25. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403-15.
26. Luscombe CA, Pederson J, Bowden S et al. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy. Liver 1994; 14: 182-92.
27. Blum HE, Stowring L, Figus A et al. Detection of hepatitis B virus DNA in hepatocytes, bile duct epithelium, and vascular elements by in situ hybridization. Proc. Natl Acad. Sci. 1983; 80: 6685-8.
28. Delladetsima JK, Vafiadis I, Tassopoulos NC et al. HBcAg and HBsAg expression in ductular cells in chronic hepatitis B. Liver 1994; 14: 71-5.
29. Jilbert AR, Freiman JS, Gowans EJ et al. Duck hepatitis B virus DNA in liver, spleen, and pancreas: Analysis by in situ and southern blot hybridization. Virology 1987; 158: 330-8.
30. Wang G, Seeger C. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 1992; 71: 663-70.
31. Gerelsaikhan T, Tavis J, Bruss V. Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis. J. Virol. 1996; 70: 4269-74.
32. Luscombe C, Locarnini S. The mechanism of action of antiviral agents in chronic hepatitis B. Viral Hep. 1996; 2: 1-35.
33. Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 1996; 24: 996-1002.
34. Hayashi Y, Koike K. Interferon inhibits hepatitis B virus replication in a stable expression system of transfected viral DNA. J. Virol. 1989; 63: 2936-40.
35. Lau JYN, Bain VG, Naomov NV et al. Effect of interferon-γ on hepatitis B viral antigen expression in primary hepatocyte culture. Hepatology 1991; 14: 975-9.
36. Weissberg JI, Andres LL, Smith CI et al. Survival in chronic hepatitis B: An analysis of 397 patients. Ann. Intern. Med. 1984; 101: 613-16.
37. Lau JYN, Bain VG, Davies SE et al. High level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992; 102: 956-62.
38. Demetris AJ. Hepatitis B after liver transplantation: New names for unusual presentations. Gastroenterology 1992; 103: 1355-6.
39. Lau JYN, Bain VG, Davies SE et al. Export of intracellular HBsAg in chronic hepatitis B virus infection is related to viral replication. Hepatology 1991; 14:416-21.
40. Jacyna M, Thomas H. Pathogenesis and treatment of chronic infection. In: Zuckerman A and Thomas H, eds. Viral hepatitis scientific basis and clinical management. London: Churchill Livingstone, 1993; 185-201.
41. Eddleston A. Immunological aspects of hepatitis B infection. In: Zuckerman A, ed. Viral hepatitis and liver disease. New York: Alan R Liss, Inc., 1987; 603-5.
42. Chisari F, Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995; 13: 29-60.
43. Tine F, Liberati A, Craxi A et al. Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature. J. Hepatol. 1993; 18: 154-61.
44. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Eng. J. Med. 1996; 334: 1422-7.
45. Fattovich G, Giustina G, Brollo L et al. Therapy for chronic hepatitis B with lymphoblastoid interferon-α and Levamisole. Hepatology 1992; 16: 1115-19.
46. Perillo RP, Regenstein FG, Roodman ST. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann. Intern. Med. 1986; 105: 382-3.
47. Novick DM, Lok ASF, Thomas HC. Diminished responsiveness of homosexual men to antiviral therapy for HBsAg-positive chronic liver disease. J. Hepatol. 1984; 1: 29-35.
48. Raptopoulou M, Orphanou H, Vrettou H et al. Interferon treatment of chronic active hepatitis B: Effect of a six month treatment regimen. Gut 1993; 34 (Suppl. 2): S102-3.
49. Wong DKH, Cheung AM, O'Rourke K et al. Effect of alpha-interferon treatment in patients with hepatitis Be antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 1993; 119: 312-23.
50. Hoofnagle JH, Lau J. Chronic viral hepatitis - Benefits of current therapies. M. Eng. J. Med. 1996; 334: 1470-1.
51. Lok ASF, Chung HT, Liu VWS et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105: 1833-8.
52. Alexander G, Williams R. Natural history and therapy of chronic hepatitis B virus infection. Am. J. Med. 1988; 85: 143-6.
53. Lok AS, Lai CL, Wu PC et al. Spontaneous hepatitis Be antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 1839-43.
54. Perillo RP, Schiff H, Davis GI. et al. A randomised controlled trial of interferon alfa-2b alone and after prednisolone withdrawal for the treatment of chronic hepatitis B. N. Eng. J. Med. 1990; 323: 295-301.
55. Reichen J, Bianchi L, Frei PC et al. Efficacy of steroid withdrawal and low-dose interferon treatment in chronic active hepatitis B. J. Hepatol. 1994; 20: 168-74.
56. Demetris AJ, Jaffe R, Sheaham DG et al. Recurrent hepatitis B in liver allograft recipients. Am. J. Pathol. 1986; 125: 161-72.
57. Ferla G, Colledan M, Doglia M et al. B hepatitis and liver transplantation. Transplant Proc. 1988; 20: 566-9.
58. Lauchart W, Muller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human allografts. Transplant Proc. 1987; 19: 4051-3.
59. Hoofnagle JH, Di Bisceglie AM, Waggoner JG et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104: 1116-21.
60. Lok ASF, Wu PC, Lai CL et al. A controlled trial of interferon with or without prednisolone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-7.
61. Lok ASF, Lai CL, Wu PC et al. Long-term follow-up in a randomised controlled trial of recombinant alpha-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 2: 298-302.
62. Romagnani S. Lymphokine production by human T cells in disease states. Annu. Rev. Immunol. 1994; 12: 227-57.
63. Clerici M, Shearer G. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol. Today 1994; 15: 575-581.
64. Gilles P, Fey G, Chisari F. Tumour necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J. Virol. 1992; 66: 3955-60.
65. Vere Hodge RA. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem. Chemother. 1993; 4: 67-84.
66. Boyd M, Safrin S, Kern K. Penciclovir: A review of its spectrum of activity, selectivity and cross-resistant pattern. Antiviral Chem. Chemother. 1993; 4 (Suppl): 3-11.
67. Shaw T, Amor P, Civitico G et al. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents Chemother. 1994; 38: 719-23.
68. Earnshaw DL, Bacon TH, Darlinson SJ et al. Mode of action of penciclovir in MRC-5 cells infected with herpes simplex virus type-1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother. 1992; 36: 2747-57.
69. Locarnini S, Lin E, Luscombe C et al. Penciclovir: A novel nucleoside analogue with potent activity against duck hepatitis B virus in vivo. Antiviral Res. 1995; 26: A242.
70. Lin E, Luscombe C, Wang YY et al. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob. Agents Chemother. 1996; 40: 413-18.
71. Tsiquaye K, Slomka M, Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J. Med. Virol. 1994; 42: 306-10.
72. Tsiquaye K, Sutton D, Maung M et al. Antiviral activities and pharmacokinetics of penciclovir and famciclovir in pekin ducks chronically infected with duck hepatitis B virus. Antiviral Chem. Chemother. 1996; 7: 153-159.
73. Mason WS, Cullen J, Saputelli J et al. Characterisation of the antiviral effects of 2'carhodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology 1994; 19: 398-411.
74. Fourel I, Saputelli J, Schaffer P et al. The carbocyclic analog of 2'-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver. J. Virol. 1994; 68: 1059-65.
75. Lee B, Luo W, Suzuki S et al. In vitro and in vivo comparison of the abilities of purine and pyrimidine 2'3'-dideoxynucleosidcs to inhibit duck hepadnavirus. Antimicrob. Agents Chemother. 1989; 33: 336-9.
76. Kruger M, Tillmann HL, Trautwein C et al. Treament of hepatitis B virus re-infection after liver transplantation with famciclovir. Hepatology 1994; 20: 130A.
77. Boker KHW, Ringe B, Kruger M et al. Prostaglandin R plus famciclovir - A new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994; 57: 1706-8.
78. Main J, Brown L, Karayiannis P et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Hepatol. 1994; 21 (Suppl: 1): S32.
79. Main J, Brown J, Howells C et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Viral Hep. 1996; 3: 211-15.
80. Trepo C. Efficacy of famciclovir in chronic hepatitis B: Results of a dose finding study. Hepatology 1996; 24: A188.
81. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob. Agents Chemother. 1994; 38: 2454-7.
82. Aye T, Bartholomeusz A, Shaw T et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J. Hepatology 1997; 26: 1148-53.
83. Wang Y, Bowden S, Shaw T et al. Inhibition of duck hepatitis B virus replication in vivo by the nucleoside analogue ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine). Antiviral Chem. Chemother. 1991; 2: 107-14.
84. Luscombe C, Pedersen J, Uren E et al. Longterm ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: Effect on intrahepatitic viral DNA, RNA and protein expression. Hepatology 1996; 24: 766-73.
85. Gish RG, Lau JYN, Brooks L et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996; 23: 1-7.
86. Angus PW, Richards M, Bowden S et al. Combination antiviral therapy controls severe post liver transplant recurrence of hepatitis B virus infection. J. Gastroenterol. Hepatol. 1993; 8: 353-7.
87. de la Mata M, Montero JL, Fraga E et al. Efficacy of ganciclovir in the treatment of hepatitis B virus infection of the liver graft. Hepatology 1995; 22 (Suppl.): 130A.
88. Locarnini S, Guo K, Lucas R et al. Inhibition of HBV-DNA replication by ganciclovir in patients with AIDS. Lancet 1989; 18: 1225-6.
89. De Clercq E. HIV inhibitors targeted at the reverse transcriptase. AIDS Research and Human Retroviruses 1992; 8: 119-34.
90. Naesens L, Neyts J, Balzarini J et al. Efficacy of oral 9-(2-phosphonylmethoxyethyl)-2, 6-diaminopurine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice. J. Med. Virol. 1993; 39: 167-73.
91. Naesens L, Balzarinin J, Bischofberger N et al. Antiretroviral activity and pharmacokinetics in mice of oral bis (pivaloyloxymethyl)-9-(2-Phosphonylmethoxyethyl)adenine, the bis (pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob. Agents Chemother. 1996; 40: 22-8.
92. Starrett JE, Tortolani DR, Hitchcock MJM et al. Synthesis and in vitro evaluation of a phosphonate prodrug: bis (pivaloyloxymethyl)9-(2-phosphonylmethoxyethyl) adenine. Antiviral Res. 1992; 19: 267-73.
93. Balzarini J, Hao Z, Herdewijn P et al. Intracellular metabolism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc. Natl Acad. Sci. USA 1991; 88: 1499-503.
94. Del Gobbo V, Foli A, Balzarini J et al. Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl) adenine (PMEA), a potent anti-HIV nucleoside analogue, on in vivo murine models. Antiviral Res. 1991; 16: 65-75.
95. Calio R, Villani N, Balestra E et al. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res. 1994; 23: 77-89.
96. Heijtink RA, De Wilde GA, Kruining J et al. Inhibitory effect of 9-2-phosphonylmethoxyethyladenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res. 1993; 21: 141-53.
97. Heijtink RA, Kruining J, De Wilde GA et al. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob. Agents Chemother. 1994; 38: 2180-2.
98. Nicoll A, Locarnini S, Chou S, Smallwood R, Angus P. Human hepatitis B virus infection of bile duct epithelial cells. Hepatology 1996; 24: 221A.
99. Srinivas RV, Robbins BL, Connelly MC et al. Metabolism and in vitro antiretroviral activities of bis (pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrob. Agents Chemother. 1993; 37: 2247-50.
100. Gilson R, Chopra K, Murray-Lyon I et al. A placebo-controlled phase I/II study of Adefovir Dipivoxil (bis-POM PMEA) in patients with chronic hepatitis B infection. Hepatology 1996; 24: 281A (Abstract).
101. Furman PA, Davis M, Liotta DC et al. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1, 3-oxanthiolan-5-yl] cytosine. Antimicrob. Agents Chemother. 1992; 36: 2686-92.
102. Furman P, Painter G. The role of absolute configuration in the anti-HIV and anti-HBV activity of nucleoside analogues. Int. Antiviral News 1995; 3: 74-7.
103. Chang CN, Doong SL, Zhou JH et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′, 3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J. Biol. Chem. 1992; 267: 13938-42.
104. Chang C, Skalski V, Zhou J et al. Biochemical pharmacology of (+) and (-)2′, 3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J. Biol. Chem. 1992; 267: 22 414-20.
105. Van Draanen NA, Tisdale M, Parry NR et al. Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrob. Agents Chemother. 1994; 38: 868-71.
106. Severini A, Liu X-Y, Wilson JS et al. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-b-L-2′, 3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 1995; 39: 1430-5.
107. Fourel I, Cullen JM, Saputelli J et al. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus During antiviral therapy of chronically infected ducks. J. Virol. 1994; 68: 8321-30.
108. Dienstag JL, Perrillo RP, Schiff ER et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Eng. J. Med. 1995; 333: 1657-61.
109. Lai CL, Ching CK, Tung A et al. Short term lamivudine suppresses HBV DNA in Chinese HBsAg carriers. Hepatology 1994; 20: 298A.
110. Tyrrell DLJ, Mitchell MC, De Man RA et al. Phase II trial of lamivudine for chronic hepatitis B. Hepatology 1993; 18: 112A.
111. Schalm SW, de Man RA, Heijtink RA et al. New nucleoside analogues for chronic hepatitis B. J. Hepatol. 1995; 22: 52-6.
112. Fong IW. Hair loss associated with lamivudine. Lancet 1994; 344: 1702.
113. Honkoop P, de Man R, Heijtink R et al. Hepatitis B reactivation after lamivudine. Lancet 1995; 346: 1156-7.
114. Tipples G, Ma M, Fischer K et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-17.
115. Bartholomew M, Jansen R, Jeffers L et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-2.
116. McKenzie R, Fried MW, Sallie R et al. Hepatic failure and lactic acidosis duc to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Eng. J. Med. 1995; 333: 1099-105.
117. Staschke K, Colacino JM. Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5′-triphosphate of fialuridine. J. Virol. 1994; 68: 8265-9.
118. Crumpacker CS. Mechanism of action of foscarnet against viral polymerases. Am. J. Med. 1992; 92: S3-7.
119. Lietman P. Clinical pharmacology: Foscarnet. Am. J. Med. 1992; 92: 8S-11S.
120. Mellors JW, Bazmi HZ, Schinazi RF et al. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob. Agents Chemother. 1995; 39: 1087-92.
121. Bain VG, Daniels HM, Chanas A et al. Foscarnet therapy in chronic hepatitis B virus e antigen carriers. J. Med. Virol. 1989; 29: 152-5.
122. Sherker AH, Hirota K, Omata M et al. Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks. Gastroenterology 1986; 91: 818-24.
123. Ruiz-Moreno M, Garcia R, Rua MJ et al. Levamisole and interferon in children with chronic hepatitis B. Hepatology 1993; 18: 264-9.
124. Carreno V, Moreno A, Galiana F et al. α-and γ-interferon versus α-interferon alone in chronic hepatitis B: A randomised controlled study. J. Hepatol. 1993; 17: 321-5.
125. Farhat BA, Marinos G, Daniels HM et al. Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J. Hepatol. 1995; 23: 21-7.
126. Janssen HLA, Berk L, Heijtink RA et al. Interferon-α and zidovudine combination therapy for chronic hepatitis B: Results of a randomised, placebo-controlled trial. Hepatology 1993; 17: 383-8.
127. Trepo C, Rougier P, Bizollon T et al. Combination therapy with ARA-AMP and interferon of chronic-active hepatitis B. J. Hepatol. 1991; 13: S3.
128. Kakumu S, Yoshioka K, Wakita T et al. Pilot study of ribavirin and interferon-β for chronic hepatitis B. Hepatology 1993; 18: 258-63.
129. Korba B. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res. 1995; 29: 49-51.
130. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997, 26: 216-25.
131. Lok ASF. Treatment of chronic hepatitis B. J. Viral Hep. 1994; 1: 105-24.
132. Perillo R, Mimms L, Schechtman K et al. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: A comparison with HBV DNA testing. Hepatology 1993; 18: 1306-12.
133. Perillo R. Antiviral therapy of chronic hepatitis B: past, present, and future. J. Hepatol. 1993; 17: S56-63.
134. Rensen PCN, Van Dijk MCM, Havenaar EC et al. Selective liver targeting of antivirals by recombinant chylomicrons - a new therapeutic approach to hepatitis B. Nat. Med. 1995; 1: 221-5.